NetraMark Holdings Inc. (PF0.F)
| Previous Close | 0.1860 |
| Open | 0.1860 |
| Bid | 0.1890 x N/A |
| Ask | 0.2380 x N/A |
| Day's Range | 0.1860 - 0.1860 |
| 52 Week Range | 0.1000 - 0.2900 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 13.633M |
| Beta (5Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CNW GroupNETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES NOVEL LUNG AND COLON CANCER BIOMARKERS AND PATIENT SUBPOPULATIONS
NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces the presentation of new data describing how its proprietary NetraAI clinical trial solution identified novel biomarkers and protein-protein interaction (PPI) pathways associated with specific forms of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) using small data sets and a self-learning algorithm that obviates
CNW GroupNETRAMARK ANNOUNCES SHAREHOLDER MEETING RESULTS
NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"), held on March 28, 2024.
CNW GroupPHARMACEUTICAL INDUSTRY VETERAN JOINS NETRAMARK ADVISORY BOARD
NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) is pleased to announce the appointment of Jeff Huntsman to its strategic advisory board. With his significant industry experience and expertise, Jeff's addition to the advisory board will further strengthen NetraMark's ability to deliver its innovative Artificial Intelligence (AI) based offerings and drive business growth.
